Effects of the BTN162b2 mRNA COVID-19 vaccine in humoral and cellular immunity in patients with chronic lymphocytic leukemia.
COVID-19
chronic lymphocytic leukemia
immunity
vaccine
Journal
Hematological oncology
ISSN: 1099-1069
Titre abrégé: Hematol Oncol
Pays: England
ID NLM: 8307268
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
revised:
09
09
2022
received:
13
07
2022
accepted:
17
09
2022
pubmed:
27
9
2022
medline:
3
2
2023
entrez:
26
9
2022
Statut:
ppublish
Résumé
Chronic lymphocytic leukemia (CLL), the most common leukemia in the western countries, is characterized by immunosuppression due to disease itself and cytotoxic treatments. Since the beginning of COVID-19 pandemic, patients with CLL appear to be a vulnerable population. In addition, phase III mRNA vaccine trials did not provide information about the efficacy in immunocomprised population. In CLL, the antibody-mediated response to SARS-CoV-2 vaccine is impaired. The goal of this study was to evaluate the effects of SARS-CoV-2 vaccination on humoral immune response and on cellular immunity in CLL patients. Humoral immune response to BNT162b2 messenger RNA COVID-19 vaccine was evaluated in 44 CLL patients comprising 20 treatment-naïve, 14 under treatment with ibrutinib and 10 in follow-up after completion of therapy. A positive serological response to SARS-CoV-2 vaccination with IgG titers higher than 13 UA/ml was detected in 54.6% of CLL patients with a higher response in patients who obtained remission after treatment. Reduced antibody response was detected in patients under ibrutinib treatment. T-cell response to overlapping pool of peptides representing the spike region was assessed in paired CLL samples collected before and after 1 month from the second dose of COVID-19 vaccine in treatment-naïve and ibrutinib-treated CLL patients using cytokine secretion assay. Both CD3+ CD4+ and CD3+ CD8+ T cells are able to mount a cellular response to spike peptides with secretion of IFNγ and TNFα before and after vaccination in both treatment naïve and ibrutinib-treated patients and this cellular immune response is independent by COVID-19 vaccination. Collectively, T cell response to spike peptides appeared more blunted in CLL patients under treatment with ibrutinib compared to untreated ones. Our study supports the need for optimization of vaccination strategy to achieve an adequate immune response keeping strict preventive measures by CLL patients against COVID-19.
Identifiants
pubmed: 36156278
doi: 10.1002/hon.3077
pmc: PMC9537931
doi:
Substances chimiques
COVID-19 Vaccines
0
BNT162 Vaccine
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
120-127Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro
Organisme : Progetto Dipartimenti di Eccellenza MIUR 2017
Informations de copyright
© 2022 The Authors. Hematological Oncology published by John Wiley & Sons Ltd.
Références
Walsh EE, Frenck RW, Falsey AR, et al. Safety and immunogenicity of two RNA-based covid-19 vaccine candidates. N Engl J Med. 2020;383(25):2439-2450. Published online October 14, 2020. https://doi.org/10.1056/NEJMoa2027906
Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369(6504):718-724. https://doi.org/10.1126/science.abc6027
Sahin U, Muik A, Vogler I, et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature. 2021;595(7868):572-577. https://doi.org/10.1038/s41586-021-03653-6
Cutucache CE. Tumor-induced host immunosuppression: special focus on CLL. Int Immunopharm. 2013;17(1):35-41. https://doi.org/10.1016/j.intimp.2013.05.021
Zent CS, Brady MT, Delage C, et al. Short term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial BTK inhibitor therapy for CLL or lymphoplasmacytic lymphoma. Leukemia. 2021;35(6):1788-1791. https://doi.org/10.1038/s41375-020-01074-4
Mauro FR, Giannarelli D, Galluzzo CM, et al. Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL). Leukemia. 2021;35(3):737-746. https://doi.org/10.1038/s41375-020-0884-z
Pleyer C, Ali MA, Cohen JI, et al. Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines. Blood. 2021;137(2):185-189. https://doi.org/10.1182/blood.2020008758
Agha M, Blake M, Chilleo C, Wells A, Haidar G. Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients. medRxiv. Published online April 7, 2021:2021.04.06.21254949. https://doi.org/10.1101/2021.04.06.21254949
Herishanu Y, Avivi I, Aharon A, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137(23):3165-3173. https://doi.org/10.1182/blood.2021011568
Roeker LE, Knorr DA, Thompson MC, et al. COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia. Leukemia. 2021;35(9):2703-2705. https://doi.org/10.1038/s41375-021-01270-w
Parry H, McIlroy G, Bruton R, et al. Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia. Blood Cancer J. 2021;11(7):1-8. https://doi.org/10.1038/s41408-021-00528-x
Herishanu Y, Avivi I, Levi S, et al. Six months antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia. Blood Adv. 2022;6(1):148-151. https://doi.org/10.1182/bloodadvances.2021005998
Tadmor T, Benjamini O, Braester A, Rahav G, Rokach L. Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia. Leukemia. 2021;35(9):2727-2730. https://doi.org/10.1038/s41375-021-01380-5
Re D, Seitz-Polski B, Brglez V, et al. Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies. Nat Commun. 2022;13(1):864. https://doi.org/10.1038/s41467-022-28578-0
Mellinghoff SC, Robrecht S, Mayer L, et al. SARS-CoV-2 specific cellular response following COVID-19 vaccination in patients with chronic lymphocytic leukemia. Leukemia. 2022;36(2):562-565. https://doi.org/10.1038/s41375-021-01500-1
Haydu JE, Maron JS, Redd RA, et al. Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study. Blood Adv. 2022;6(6):1671-1683. https://doi.org/10.1182/bloodadvances.2021006627
Forconi F, Moss P. Perturbation of the normal immune system in patients with CLL. Blood. 2015;126(5):573-581. https://doi.org/10.1182/blood-2015-03-567388
Puzzolo MC, Del Giudice I, Peragine N, et al. TH2/TH1 shift under ibrutinib treatment in chronic lymphocytic leukemia. Front Oncol. 2021;11:637186. https://doi.org/10.3389/fonc.2021.637186
Ujjani C, Shadman M, Lynch RC, et al. The impact of B-cell-directed therapy on SARS-CoV-2 vaccine efficacy in chronic lymphocytic leukaemia. Br J Haematol. 2022;197(3):306-309. https://doi.org/10.1111/bjh.18088
Molica S, Tam C, Polliack A. Current perspectives regarding SARS-CoV-2 vaccination in chronic lymphocytic leukemia. Hematol Oncol. 2022;40(3):313-319. https://doi.org/10.1002/hon.2990
Morawska M. Reasons and consequences of COVID-19 vaccine failure in patients with chronic lymphocytic leukemia. Eur J Haematol. 2022;108(2):91-98. https://doi.org/10.1111/ejh.13722
Sun C, Tian X, Lee YS, et al. Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood. 2015;126(19):2213-2219. https://doi.org/10.1182/blood-2015-04-639203
Douglas AP, Trubiano JA, Barr I, Leung V, Slavin MA, Tam CS. Ibrutinib may impair serological responses to influenza vaccination. Haematologica. 2017;102(10):e397-e399. https://doi.org/10.3324/haematol.2017.164285
Lyski ZL, Kim MS, Xthona Lee D, et al. Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia. Blood Adv. 2022;6(4):1207-1211. https://doi.org/10.1182/bloodadvances.2021006633
Mellinghoff SC, Mayer L, Robrecht S, et al. SARS-CoV-2-specific cellular response following third COVID-19 vaccination in patients with chronic lymphocytic leukemia. Haematologica. Published online June 23, 2022. https://doi.org/10.3324/haematol.2022.280982